MedTrace Logo

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

NCT03417739 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.

Conditions

Interventions

DRUG

BVD-523

ERK1 and ERK2 inhibitor

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Buchbinder, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2020-05-05
Completion
2025-07-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417739 on ClinicalTrials.gov